Startseite>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Pivmecillinam hydrochloride (FL-1039 hydrochloride)

Pivmecillinam hydrochloride (FL-1039 hydrochloride)

Katalog-Nr.GC32175

Pivmecillinam-Hydrochlorid (FL-1039-Hydrochlorid) (FL-1039-Hydrochlorid) ist ein oral aktives Prodrug von Mecillinam, einem Penicillin-Antibiotikum mit erweitertem Wirkungsspektrum.

Products are for research use only. Not for human use. We do not sell to patients.

Pivmecillinam hydrochloride (FL-1039 hydrochloride) Chemische Struktur

Cas No.: 32887-03-9

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
53,00 $
Auf Lager
10mg
47,00 $
Auf Lager
50mg
147,00 $
Auf Lager
100mg
258,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pivmecillinam hydrochloride (FL-1039 hydrochloride) is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

[1]. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother. 2000 Aug;46 Suppl A:35-39. [2]. Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:73-8. [3]. Holme E, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet. 1989 Aug 26;2(8661):469-73.

Bewertungen

Review for Pivmecillinam hydrochloride (FL-1039 hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pivmecillinam hydrochloride (FL-1039 hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.